---
http_interactions:
- request:
    method: post
    uri: https://sciencewirerest.discoverylogic.com/PublicationCatalog/PublicationQuery?format=xml
    body:
      encoding: US-ASCII
      string: ! "<?xml version=\"1.0\"?>\n      <ScienceWireQueryXMLParameter xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\"
        xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\">\n      <xmlQuery><![CDATA[\n\t
        \    <query xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:xsd=\"http://www.w3.org/2001/\n\t
        \   XMLSchema\">\n\t      <Criterion ConjunctionOperator=\"AND\">\n\t        <Criteria><Criterion>\n\t
        \           <Filter>\n\t              <Column>Title</Column>\n\t              <Operator>Contains</Operator>\n\t
        \             <Value>lung cancer treatment</Value>\n\t            </Filter>\n\t
        \         </Criterion></Criteria>\n\t      </Criterion>\n\t      <Columns>\n\t
        \       <SortColumn>\n\t          <Column>Rank</Column>\n\t          <Direction>Descending</Direction>\n\t
        \       </SortColumn>\n\t      </Columns>\n\t     <MaximumRows>20</MaximumRows>\n\t
        \   </query>\n\t    ]]></xmlQuery>\n      </ScienceWireQueryXMLParameter>"
    headers:
      Accept:
      - ! '*/*'
      User-Agent:
      - Ruby
      Licenseid:
      - ***REMOVED***
      Host:
      - sciencewirerest.discoverylogic.com
      Connection:
      - Keep-Alive
      Expect:
      - 100-continue
      Content-Type:
      - text/xml
  response:
    status:
      code: 200
      message: OK
    headers:
      Cache-Control:
      - private
      Content-Type:
      - application/xml; charset=utf-8
      Server:
      - Microsoft-IIS/7.5
      X-Aspnetmvc-Version:
      - '2.0'
      X-Aspnet-Version:
      - 4.0.30319
      X-Powered-By:
      - ASP.NET
      Date:
      - Sun, 08 Sep 2013 20:09:51 GMT
      Content-Length:
      - '279'
    body:
      encoding: US-ASCII
      string: ! "<?xml version=\"1.0\"?>\r\n<ScienceWireQueryIDResponse xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\"
        xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\r\n  <queryID>50106</queryID>\r\n
        \ <queryResultRows>20</queryResultRows>\r\n  <totalRows>20</totalRows>\r\n</ScienceWireQueryIDResponse>"
    http_version: 
  recorded_at: Sun, 08 Sep 2013 20:09:51 GMT
- request:
    method: get
    uri: https://sciencewirerest.discoverylogic.com/PublicationCatalog/PublicationQuery/50106?format=xml&page=0&pageSize=2147483647&v=version/3
    body:
      encoding: US-ASCII
      string: ''
    headers:
      Accept:
      - ! '*/*'
      User-Agent:
      - Ruby
      Content-Type:
      - text/xml
      Licenseid:
      - ***REMOVED***
      Host:
      - sciencewirerest.discoverylogic.com
      Connection:
      - Keep-Alive
  response:
    status:
      code: 200
      message: OK
    headers:
      Cache-Control:
      - private
      Content-Type:
      - application/xml; charset=utf-8
      Server:
      - Microsoft-IIS/7.5
      X-Aspnetmvc-Version:
      - '2.0'
      X-Aspnet-Version:
      - 4.0.30319
      X-Powered-By:
      - ASP.NET
      Date:
      - Sun, 08 Sep 2013 20:09:51 GMT
      Content-Length:
      - '57724'
    body:
      encoding: US-ASCII
      string: ! "<?xml version=\"1.0\"?>\r\n<ArrayOfPublicationItem xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\"
        xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>63687762</PublicationItemID>\r\n    <Title>Assessment
        of the Impact of FDG-PET on Lung Cancer Treatment.</Title>\r\n    <Abstract
        />\r\n    <AuthorList>Ashish,A,|Menzes,B,|Sheppard,S,|Walker,P,P</AuthorList>\r\n
        \   <AuthorCount>4</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Meeting
        Abstract</DocumentTypeList>\r\n    <DocumentCategory>Conference Proceeding
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000208733103711</WoSItemID>\r\n
        \   <PublicationSourceTitle>AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE
        MEDICINE</PublicationSourceTitle>\r\n    <Volume>179</Volume>\r\n    <Pagination
        />\r\n    <PublicationDate>2009-01-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2009</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Critical
        Care Medicine|Respiratory System</PublicationSubjectCategoryList>\r\n    <ISSN>1073-449X</ISSN>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>0</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>AMER THORACIC
        SOC</CopyrightPublisher>\r\n    <CopyrightCity>NEW YORK</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>10.689,2009,ExactPublicationYear|11.08,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>1/22;CRITICAL CARE MEDICINE;2009;SC;ExactPublicationYear|1/43;RESPIRATORY
        SYSTEM;2009;SC;ExactPublicationYear|1/26;CRITICAL CARE MEDICINE;2011;SC;MostRecentYear|1/48;RESPIRATORY
        SYSTEM;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>63624517</PublicationItemID>\r\n    <Title>The evolution
        of lung cancer treatment.</Title>\r\n    <Abstract />\r\n    <AuthorList />\r\n
        \   <AuthorCount>0</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Editorial</DocumentTypeList>\r\n
        \   <DocumentCategory>Other</DocumentCategory>\r\n    <NumberOfReferences
        xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\" />\r\n    <TimesNotSelfCited
        xsi:nil=\"true\" />\r\n    <PMID>23890032</PMID>\r\n    <PublicationSourceTitle>Lancet</PublicationSourceTitle>\r\n
        \   <Volume>382</Volume>\r\n    <Issue>9889</Issue>\r\n    <Pagination>286-?</Pagination>\r\n
        \   <PublicationDate>2013-07-27T00:00:00</PublicationDate>\r\n    <PublicationYear>2013</PublicationYear>\r\n
        \   <PublicationSubjectCategoryList />\r\n    <ISSN>0140-6736</ISSN>\r\n    <DOI>10.1016/S0140-6736(13)61619-0</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>1</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>ELSEVIER
        LTD</CopyrightPublisher>\r\n    <CopyrightCity />\r\n    <PublicationImpactFactorList>38.278,2011,ClosestToPublicationYear|38.278,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>2/153;MEDICINE, GENERAL &amp; INTERNAL;2011;SC;ClosestToPublicationYear|2/153;MEDICINE,
        GENERAL &amp; INTERNAL;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED KINGDOM</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>63390937</PublicationItemID>\r\n
        \   <Title>Adapting to the Brave New World of Lung Cancer Treatment</Title>\r\n
        \   <Abstract />\r\n    <AuthorList>Pinder-Schenck,Mary,C|Antonia,Scott,J</AuthorList>\r\n
        \   <AuthorCount>2</AuthorCount>\r\n    <KeywordList>ERLOTINIB|TRIAL|KRAS|GEFITINIB</KeywordList>\r\n
        \   <DocumentTypeList>Editorial Material</DocumentTypeList>\r\n    <DocumentCategory>Other</DocumentCategory>\r\n
        \   <NumberOfReferences>8</NumberOfReferences>\r\n    <TimesCited>0</TimesCited>\r\n
        \   <TimesNotSelfCited>0</TimesNotSelfCited>\r\n    <PMID xsi:nil=\"true\"
        />\r\n    <WoSItemID>000319621100010</WoSItemID>\r\n    <PublicationSourceTitle>ONCOLOGY-NEW
        YORK</PublicationSourceTitle>\r\n    <Volume>27</Volume>\r\n    <Issue>5</Issue>\r\n
        \   <Pagination>411-412</Pagination>\r\n    <PublicationDate>2013-05-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2013</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0890-9091</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\" />\r\n
        \   <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\" />\r\n
        \   <OrdinalRank>2</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\" />\r\n
        \   <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>UBM MEDICA</CopyrightPublisher>\r\n    <CopyrightCity>NORWALK</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>1.026,2011,ClosestToPublicationYear|1.026,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>163/190;ONCOLOGY;2011;SC;ClosestToPublicationYear|163/190;ONCOLOGY;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0</AuthorCitationCountList>\r\n    <CopyrightStateProvince>CT</CopyrightStateProvince>\r\n
        \   <CopyrightCountry>UNITED STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n
        \ <PublicationItem>\r\n    <PublicationItemID>63340592</PublicationItemID>\r\n
        \   <Title>Molecularly targeted approaches herald a new era of non-small-cell
        lung cancer treatment.</Title>\r\n    <Abstract>The discovery of activating
        mutations in the epidermal growth-factor receptor (EGFR) gene in 2004 opened
        a new era of personalized treatment for non-small-cell lung cancer (NSCLC).
        EGFR mutations are associated with a high sensitivity to EGFR tyrosine kinase
        inhibitors, such as gefitinib and erlotinib. Treatment with these agents in
        EGFR-mutant NSCLC patients results in dramatically high response rates and
        prolonged progression-free survival compared with conventional standard chemotherapy.
        Subsequently, echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic
        lymphoma kinase (ALK), a novel driver oncogene, has been found in 2007. Crizotinib,
        the first clinically available ALK tyrosine kinase inhibitor, appeared more
        effective compared with standard chemotherapy in NSCLC patients harboring
        EML4-ALK. The identification of EGFR mutations and ALK rearrangement in NSCLC
        has further accelerated the shift to personalized treatment based on the appropriate
        patient selection according to detailed molecular genetic characterization.
        This review summarizes these genetic biomarker-based approaches to NSCLC,
        which allow the instigation of individualized therapy to provide the desired
        clinical outcome.</Abstract>\r\n    <AuthorList>Kaneda,Hiroyasu,|Yoshida,Takeshi,|Okamoto,Isamu,</AuthorList>\r\n
        \   <AuthorCount>3</AuthorCount>\r\n    <KeywordList>ALK rearrangement|crizotinib|epidermal
        growth factor receptor|erlotinib|gefitinib|non-small-cell lung cancer</KeywordList>\r\n
        \   <DocumentTypeList>Journal Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited xsi:nil=\"true\" />\r\n    <TimesNotSelfCited xsi:nil=\"true\"
        />\r\n    <PMID>23785245</PMID>\r\n    <PublicationSourceTitle>Cancer management
        and research</PublicationSourceTitle>\r\n    <Volume>5</Volume>\r\n    <Pagination>91-101</Pagination>\r\n
        \   <PublicationDate>2013-01-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2013</PublicationYear>\r\n
        \   <PublicationSubjectCategoryList />\r\n    <ISSN>1179-1322</ISSN>\r\n    <DOI>10.2147/CMAR.S32973</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>3</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <CopyrightStateProvince />\r\n    <CopyrightCountry>NEW
        ZEALAND</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>63262932</PublicationItemID>\r\n    <Title>Gefitinib
        in combination with prednisolone to avoid interstitial lung disease during
        non-small cell lung cancer treatment: A case report</Title>\r\n    <Abstract>Gefitinib-induced
        interstitial lung disease (ILD) is a rare but lethal drug adverse event, which
        usually leads to the withdrawal of gefitinib and causes complications with
        anticancer treatment. In this study, gefitinib administration combined with
        prednisolone in a female with stage IIIb non-small cell lung cancer (NSCLC)
        produced a good outcome without inducing ILD. The results suggested that combined
        administration of gefitinib with glucocorticoids may be an efficient method
        to treat NSCLC while avoiding complications with ILD.</Abstract>\r\n    <AuthorList>Xue,Xinying,|Xue,Qingliang,|Liu,Yuxia,|Pan,Lei,|Wang,Kaifei,|Zhang,Lina,|Wang,Na,|Yang,Bing,|Wang,Jianxin,</AuthorList>\r\n
        \   <AuthorCount>9</AuthorCount>\r\n    <KeywordList>interstitial lung disease|prednisolone|combination
        treatment|non-small cell lung cancer|gefitinib</KeywordList>\r\n    <DocumentTypeList>Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>9</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000318385500032</WoSItemID>\r\n
        \   <PublicationSourceTitle>ONCOLOGY LETTERS</PublicationSourceTitle>\r\n
        \   <Volume>5</Volume>\r\n    <Issue>5</Issue>\r\n    <Pagination>1599-1600</Pagination>\r\n
        \   <PublicationDate>2013-05-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2013</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1792-1074</ISSN>\r\n    <DOI>10.3892/ol.2013.1212</DOI>\r\n    <ConferenceStartDate
        xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank
        xsi:nil=\"true\" />\r\n    <OrdinalRank>4</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>SPANDIDOS PUBL LTD</CopyrightPublisher>\r\n    <CopyrightCity>ATHENS</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>0.108,2011,ClosestToPublicationYear|0.108,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>189/190;ONCOLOGY;2011;SC;ClosestToPublicationYear|189/190;ONCOLOGY;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0|8,0,0|9,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>GREECE</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>63227447</PublicationItemID>\r\n
        \   <Title>A Multicenter Randomized Phase IIb Efficacy Study of Vx-001, a
        Peptide-Based Cancer Vaccine as Maintenance Treatment in Advanced Non-Small-Cell
        Lung Cancer: Treatment Rationale and Protocol Dynamics</Title>\r\n    <Abstract>We
        present the treatment rationale and study design of a multicenter, open-label,
        randomized, 2-arm, phase IIb study. Patients with stage IV or recurrent stage
        I to III non-small-cell lung cancer (NSCLC) whose disease does not progress
        after 4 cycles of first-line platinum-based chemotherapy will be randomized
        in a 1: 1 ratio to 1 of 2 study arms. Patients will receive the cancer vaccine
        Vx-001 + Montanide ISA51 VG (Seppic, Paris, France) adjuvant subcutaneously,
        at a dose of 2 mg, or placebo + Montanide ISA51 VG adjuvant subcutaneously.
        The vaccination protocol comprises 2 injections with the TYR-Vx001 or placebo
        (1 at day 0 and another at week 3) and 4 injections with the ARG-Vx001 or
        placebo, at weeks 6, 9, 12, and 15. After the treatment assessment at week
        18, patients will receive the ARG-Vx001 or placebo every 12 weeks starting
        from week 27 until disease progression, unacceptable toxicity, withdrawal
        of informed consent, or death. The primary end point of this study is the
        survival rate at 12 months. Secondary end points include time-to-event comparison
        of overall survival and comparison of time to treatment failure. Exploratory
        objectives include comparison of disease control rate after the end of subsequent
        second-line treatments, comparisons of vaccine immune responses, comparison
        of survival rate at 12 months in patients with vaccine-induced immune response
        detected after the second and sixth injections, identification of biomarkers
        on lymphocytes and on tumors, and comparison of safety and tolerability. (C)
        2013 Elsevier Inc. All rights reserved.</Abstract>\r\n    <AuthorList>Georgoulias,Vassilis,|Douillard,Jean-Yves,|Khayat,David,|Manegold,Christian,|Rosell,Rafael,|Rossi,Antonio,|Menez-Jamet,Jeanne,|Iche,Marina,|Kosmatopoulos,Kostas,|Gridelli,Cesare,</AuthorList>\r\n
        \   <AuthorCount>10</AuthorCount>\r\n    <KeywordList>CLINICAL-PRACTICE GUIDELINES|CARCINOMA|IMMUNOTHERAPY|PLACEBO|EDITION|EPITOPES|BEVACIZUMAB|TERT572Y|first-line|vaccination|clinical
        trial|telomerase reverse transcriptase (TERT)|Metastatic/recurrent non-small-cell
        lung cancer (NSCLC)</KeywordList>\r\n    <DocumentTypeList>Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>22</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>23647738</PMID>\r\n    <WoSItemID>000320499300021</WoSItemID>\r\n
        \   <PublicationSourceTitle>CLINICAL LUNG CANCER</PublicationSourceTitle>\r\n
        \   <Volume>14</Volume>\r\n    <Issue>4</Issue>\r\n    <Pagination>461-465</Pagination>\r\n
        \   <PublicationDate>2013-07-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2013</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1525-7304</ISSN>\r\n    <DOI>10.1016/j.cllc.2013.02.001</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>5</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>CIG MEDIA
        GROUP, LP</CopyrightPublisher>\r\n    <CopyrightCity>DALLAS</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>2.944,2011,ClosestToPublicationYear|2.944,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>78/190;ONCOLOGY;2011;SC;ClosestToPublicationYear|78/190;ONCOLOGY;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0|8,0,0|9,0,0|10,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>TX</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>63070594</PublicationItemID>\r\n    <Title>Membrane
        Phospholipids, EML4-ALK, and Hsp90 as Novel Targets in Lung Cancer Treatment</Title>\r\n
        \   <Abstract>Approximately one third of patients with non-small cell lung
        cancer have unresectable stage IIIA or stage IIIB disease; combined cytotoxic
        chemotherapy and radiation therapy delivered concurrently has been established
        as the standard treatment for such patients. Despite many clinical trials
        that tested several different radiochemotherapy combinations, it seems that
        a plateau of efficiencies at the acceptable risk of complications has been
        reached. Clinical studies indicate that the improved efficacy of radiochemotherapy
        is associated with the radiosensitizing effects of chemotherapy. Improvement
        of outcomes of this combined modality by developing novel radiosensitizers
        is a viable therapeutic strategy. In addition to causing cell death, ionizing
        radiation also induces a many-faceted signaling response, which activates
        numerous prosurvival pathways that lead to enhanced proliferation in the endothelial
        cells and increased vascularization in tumors. Radiation at doses used in
        the clinic activates cytoplasmic phospholipase A2, leading to increased production
        of arachidonic acid and lysophosphatidylcholine. The former is the initial
        step in the generation of eicosanoids, while the later is the initial step
        in the formation of lysophosphatidic acid, leading to the activation of inflammatory
        pathways. The echinoderm microtubule-associated protein-like 4 anaplastic
        lymphoma kinase (EML4-ALK) is member of the insulin superfamily of receptor
        tyrosine kinases. The EML4-ALK fusion gene appears unique to lung cancer and
        signals through extracellular signal regulated kinase and phosphoinositide
        3-kinase. Heat shock protein 90 (Hsp90) is often overexpressed and present
        in an activated multichaperone complex in cancer cells, and it is now regarded
        as essential for malignant transformation and progression. In this review
        we focus on radiosensitizing strategies involving the targeting of membrane
        phospholipids, EML4-ALK, and Hsp90 with specific inhibitors and briefly discuss
        the combination of radiation with antivascular agents.</Abstract>\r\n    <AuthorList>Laszlo,Andrei,|Thotala,Dinesh,|Hallahan,Dennis,E</AuthorList>\r\n
        \   <AuthorCount>3</AuthorCount>\r\n    <KeywordList>PROGNOSTIC-SIGNIFICANCE|CYCLOOXYGENASE-2
        EXPRESSION|LYSOPHOSPHATIDIC ACID|ANAPLASTIC LYMPHOMA KINASE|TUMOR-CELL LINES|PHASE-III|MOLECULAR
        CHAPERONE|RADIATION SENSITIVITY|CYTOSOLIC PHOSPHOLIPASE-A2|ONCOGENE ADDICTION|NSCLC|radiochemotherapy|Hsp90|radiotherapy|cPLA2|ATX|EML4-ALK</KeywordList>\r\n
        \   <DocumentTypeList>Review</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>134</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>23708071</PMID>\r\n    <WoSItemID>000319557700009</WoSItemID>\r\n
        \   <PublicationSourceTitle>CANCER JOURNAL</PublicationSourceTitle>\r\n    <Volume>19</Volume>\r\n
        \   <Issue>3</Issue>\r\n    <Pagination>238-246</Pagination>\r\n    <PublicationDate>2013-05-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2013</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1528-9117</ISSN>\r\n    <DOI>10.1097/PPO.0b013e31829a68eb</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>6</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>LIPPINCOTT
        WILLIAMS &amp; WILKINS</CopyrightPublisher>\r\n    <CopyrightCity>PHILADELPHIA</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>3.256,2011,ClosestToPublicationYear|3.256,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>70/190;ONCOLOGY;2011;SC;ClosestToPublicationYear|70/190;ONCOLOGY;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>PA</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>63037727</PublicationItemID>\r\n    <Title>[Interstitial
        lung disease associated with lung cancer treatment].</Title>\r\n    <Abstract>Interstitial
        lung disease is one of the most serious side effects caused by lung cancer
        treatment. Due to the complexity diagnosis and variability of the disease,
        it is often not diagnosied and treated in time, even endanger the patient's
        life and affect the patient's prognosis. The mechanism of interstitial pneumonia
        caused by radiotherapy, chemotherapy and targeted therapy is still not fully
        known. Therefore, it become a problem that how to early detection, diagnosis
        and treat the interstitial lung disease caused by lung cancer treatment and
        it should not be ignored in the future.</Abstract>\r\n    <AuthorList>Cao,Zhiwei,|Jin,Shi,|Yu,Yan,</AuthorList>\r\n
        \   <AuthorCount>3</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>English
        Abstract|Journal Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited xsi:nil=\"true\" />\r\n    <TimesNotSelfCited xsi:nil=\"true\"
        />\r\n    <PMID>23676984</PMID>\r\n    <PublicationSourceTitle>Zhongguo fei
        ai za zhi = Chinese journal of lung cancer</PublicationSourceTitle>\r\n    <Volume>16</Volume>\r\n
        \   <Issue>5</Issue>\r\n    <Pagination>267-272</Pagination>\r\n    <PublicationDate>2013-05-20T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2013</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>1009-3419</ISSN>\r\n    <DOI>10.3779/j.issn.1009-3419.2013.05.09</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>7</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <CopyrightStateProvince />\r\n    <CopyrightCountry>CHINA</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>62915966</PublicationItemID>\r\n
        \   <Title>The Role of Pretreatment PET/CT Parameters in Predicting Response
        after Lung Cancer Treatment</Title>\r\n    <Abstract />\r\n    <AuthorList>Lavaf,A,|Tejwani,A,|DAYA,P,|Atia,M,|Ashamalla,H,</AuthorList>\r\n
        \   <AuthorCount>5</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Meeting
        Abstract</DocumentTypeList>\r\n    <DocumentCategory>Conference Proceeding
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000317035000307</WoSItemID>\r\n
        \   <PublicationSourceTitle>JOURNAL OF THORACIC ONCOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>7</Volume>\r\n    <Issue>9</Issue>\r\n    <Pagination>S319-S319</Pagination>\r\n
        \   <PublicationDate>2012-09-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2012</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology|Respiratory
        System</PublicationSubjectCategoryList>\r\n    <ISSN>1556-0864</ISSN>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>8</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>LIPPINCOTT
        WILLIAMS &amp; WILKINS</CopyrightPublisher>\r\n    <CopyrightCity>PHILADELPHIA</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>3.661,2011,ClosestToPublicationYear|3.661,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>54/190;ONCOLOGY;2011;SC;ClosestToPublicationYear|9/48;RESPIRATORY
        SYSTEM;2011;SC;ClosestToPublicationYear|54/190;ONCOLOGY;2011;SC;MostRecentYear|9/48;RESPIRATORY
        SYSTEM;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>PA</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>62877714</PublicationItemID>\r\n    <Title>Anaplastic
        lymphoma kinase: a glimmer of hope in lung cancer treatment?</Title>\r\n    <Abstract>Anaplastic
        lymphoma kinase (ALK) rearrangements (ALK-Rs) have been identified in 3-7%
        of all non-small-cell lung cancers (NSCLCs) and represent an important molecular
        target for NSCLC treatment. The authors discuss the role of ALK-Rs in the
        prediction of clinical pathological features of NSCLCs and the technical problems
        related to their determination in specimens. The authors also describe the
        preclinical and clinical results derived from the use of ALK inhibitors. ALK-R
        is generally detected in patients with specific clinical pathological features:
        never-smokers, young males, adenocarcinoma histotype and EGF receptor/KRAS
        wild-type. The diagnosis of ALK-R remains a challenge, implicating the need
        of a careful filtering of patients. NSCLC patients harboring ALK-R have shown
        sensitivity to ALK inhibitors even if their activity is limited at the time
        by the occurrence of mechanisms of resistance. The authors summarize the strategies
        that in the future could overcome these mechanisms of escape.</Abstract>\r\n
        \   <AuthorList>Franco,Renato,|Rocco,Gaetano,|Marino,Federica,Zito|Pirozzi,Giuseppe,|Normanno,Nicola,|Morabito,Alessandro,|Sperlongano,Pasquale,|Stiuso,Paola,|Luce,Amalia,|Botti,Gerardo,|Caraglia,Michele,</AuthorList>\r\n
        \   <AuthorCount>11</AuthorCount>\r\n    <KeywordList>GROWTH-FACTOR-RECEPTOR|RESISTANCE|INHIBITOR|ADENOCARCINOMA|EGFR|MUTATIONS|UP-REGULATION|ALK
        GENE|EML4-ALK FUSION GENE|SMALL-CELL-LUNG|molecular biology|non-small-cell
        lung cancer|anaplastic lymphoma kinase|lung cancer diagnosis|lung cancer biology|crizotinib</KeywordList>\r\n
        \   <DocumentTypeList>Review</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>80</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>23560836</PMID>\r\n    <WoSItemID>000318141600009</WoSItemID>\r\n
        \   <PublicationSourceTitle>EXPERT REVIEW OF ANTICANCER THERAPY</PublicationSourceTitle>\r\n
        \   <Volume>13</Volume>\r\n    <Issue>4</Issue>\r\n    <Pagination>407-420</Pagination>\r\n
        \   <PublicationDate>2013-04-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2013</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1473-7140</ISSN>\r\n    <DOI>10.1586/ERA.13.18</DOI>\r\n    <ConferenceStartDate
        xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank
        xsi:nil=\"true\" />\r\n    <OrdinalRank>9</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>EXPERT REVIEWS</CopyrightPublisher>\r\n    <CopyrightCity>LONDON</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>2.652,2011,ClosestToPublicationYear|2.652,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>88/190;ONCOLOGY;2011;SC;ClosestToPublicationYear|88/190;ONCOLOGY;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0|8,0,0|9,0,0|10,0,0|11,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED KINGDOM</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>62529832</PublicationItemID>\r\n
        \   <Title>Pemetrexed-induced cellulitis: a rare toxicity in non-small cell
        lung cancer treatment.</Title>\r\n    <Abstract>Pemetrexed is indicated for
        locally advanced or metastatic non-squamous non-small-cell lung cancer as
        an initial treatment in combination with cisplatin or after prior chemotherapy
        as a single agent. It is generally a well-tolerated drug. The most common
        adverse reactions (incidence = 20%) with single-agent use are fatigue, nausea,
        and anorexia. Additional common side effects when used in combination with
        cisplatin include vomiting, neutropenia, leukopenia, anemia, stomatitis/pharyngitis,
        thrombocytopenia, and constipation. Peripheral edema with associated erythema
        has rarely been described as an adverse effect. Herein, we report a patient
        with advanced non-small-cell lung cancer who experienced bilateral peripheral
        edema after pemetrexed administration. Discontinuation of pemetrexed and corticosteroids
        use completely resolved peripheral edema.</Abstract>\r\n    <AuthorList>Katsenos,Stamatis,|Psara,Anthoula,|Panagou,Chara,</AuthorList>\r\n
        \   <AuthorCount>3</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Journal
        Article</DocumentTypeList>\r\n    <DocumentCategory>Journal Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\"
        />\r\n    <TimesNotSelfCited xsi:nil=\"true\" />\r\n    <PMID>22357637</PMID>\r\n
        \   <PublicationSourceTitle>Journal of oncology pharmacy practice : official
        publication of the International Society of Oncology Pharmacy Practitioners</PublicationSourceTitle>\r\n
        \   <Volume>19</Volume>\r\n    <Issue>1</Issue>\r\n    <Pagination>93-94</Pagination>\r\n
        \   <PublicationDate>2013-03-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2013</PublicationYear>\r\n
        \   <PublicationSubjectCategoryList />\r\n    <ISSN>1078-1552</ISSN>\r\n    <DOI>10.1177/1078155212438453</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>10</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED
        KINGDOM</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>62413416</PublicationItemID>\r\n    <Title>Socioeconomic
        Inequalities in Lung Cancer Treatment: Systematic Review and Meta-Analysis</Title>\r\n
        \   <Abstract>Background: Intervention-generated inequalities are unintended
        variations in outcome that result from the organisation and delivery of health
        interventions. Socioeconomic inequalities in treatment may occur for some
        common cancers. Although the incidence and outcome of lung cancer varies with
        socioeconomic position (SEP), it is not known whether socioeconomic inequalities
        in treatment occur and how these might affect mortality. We conducted a systematic
        review and meta-analysis of existing research on socioeconomic inequalities
        in receipt of treatment for lung cancer.  Methods and Findings: MEDLINE, EMBASE,
        and Scopus were searched up to September 2012 for cohort studies of participants
        with a primary diagnosis of lung cancer (ICD10 C33 or C34), where the outcome
        was receipt of treatment (rates or odds of receiving treatment) and where
        the outcome was reported by a measure of SEP. Forty-six papers met the inclusion
        criteria, and 23 of these papers were included in meta-analysis. Socioeconomic
        inequalities in receipt of lung cancer treatment were observed. Lower SEP
        was associated with a reduced likelihood of receiving any treatment (odds
        ratio [OR] = 0.79 [95% CI 0.73 to 0.86], p&lt;0.001), surgery (OR = 0.68 [CI
        0.63 to 0.75], p&lt;0.001) and chemotherapy (OR = 0.82 [95% CI 0.72 to 0.93],
        p = 0.003), but not radiotherapy (OR = 0.99 [95% CI 0.86 to 1.14], p = 0.89),
        for lung cancer. The association remained when stage was taken into account
        for receipt of surgery, and was found in both universal and non-universal
        health care systems.  Conclusions: Patients with lung cancer living in more
        socioeconomically deprived circumstances are less likely to receive any type
        of treatment, surgery, and chemotherapy. These inequalities cannot be accounted
        for by socioeconomic differences in stage at presentation or by differences
        in health care system. Further investigation is required to determine the
        patient, tumour, clinician, and system factors that may contribute to socioeconomic
        inequalities in receipt of lung cancer treatment.</Abstract>\r\n    <AuthorList>Forrest,Lynne,F|Adams,Jean,|Wareham,Helen,|Rubin,Greg,|White,Martin,</AuthorList>\r\n
        \   <AuthorCount>5</AuthorCount>\r\n    <KeywordList>RACIAL DISPARITIES|SURGERY|SURVIVAL|MANAGEMENT|STAGE|ACCESS|NEW-ZEALAND|SURGICAL-TREATMENT|SOUTH
        EAST ENGLAND|TREATMENT PATTERNS</KeywordList>\r\n    <DocumentTypeList>Review</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>72</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>23393428</PMID>\r\n    <WoSItemID>000315592800001</WoSItemID>\r\n
        \   <PublicationSourceTitle>PLOS MEDICINE</PublicationSourceTitle>\r\n    <Volume>10</Volume>\r\n
        \   <Issue>2</Issue>\r\n    <Pagination />\r\n    <PublicationDate>2013-02-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2013</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Medicine, General &amp; Internal</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1549-1676</ISSN>\r\n    <DOI>10.1371/journal.pmed.1001376</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>11</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>PUBLIC
        LIBRARY SCIENCE</CopyrightPublisher>\r\n    <CopyrightCity>SAN FRANCISCO</CopyrightCity>\r\n
        \   <ArticleNumber>e1001376</ArticleNumber>\r\n    <PublicationImpactFactorList>16.269,2011,ClosestToPublicationYear|16.269,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>5/153;MEDICINE, GENERAL &amp; INTERNAL;2011;SC;ClosestToPublicationYear|5/153;MEDICINE,
        GENERAL &amp; INTERNAL;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>CA</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>62405361</PublicationItemID>\r\n    <Title>A chrono-target
        chemotherapy treatment model for lung cancer treatment.</Title>\r\n    <Abstract
        />\r\n    <AuthorList>Zarogoulidis,Paul,|Trakada,Georgia,|Zarogoulidis,Konstantinos,</AuthorList>\r\n
        \   <AuthorCount>3</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Editorial</DocumentTypeList>\r\n
        \   <DocumentCategory>Other</DocumentCategory>\r\n    <NumberOfReferences
        xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\" />\r\n    <TimesNotSelfCited
        xsi:nil=\"true\" />\r\n    <PMID>23323775</PMID>\r\n    <PublicationSourceTitle>Therapeutic
        delivery</PublicationSourceTitle>\r\n    <Volume>4</Volume>\r\n    <Issue>1</Issue>\r\n
        \   <Pagination>5-8</Pagination>\r\n    <PublicationDate>2013-01-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2013</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>2041-5990</ISSN>\r\n    <DOI>10.4155/tde.12.137</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>12</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED
        KINGDOM</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>62402512</PublicationItemID>\r\n    <Title>Thromboprophylaxis
        in ambulatory lung cancer treatment.</Title>\r\n    <Abstract>Venous thromboembolism
        (VTE), including deep vein thrombosis and pulmonary embolism, are common problems
        experienced by patients with lung cancer that can impact treatment plans,
        prognoses, and survival. Patients with lung cancer are at greatest risk for
        development of VTE in the ambulatory care treatment setting. Literature does
        exist on VTE management for medical and surgical oncology inpatients, as well
        as clinical guidelines for inpatient prophylaxis; however, published evidence
        is lacking on outpatient risk and thromboprophylaxis in medical oncology outpatients,
        particularly patients with lung cancer. Because patients with lung cancer
        treated in the ambulatory setting have established risks for VTE, they may
        benefit from thromboprophylaxis. Clinical guidelines for outpatient thromboprophylaxis
        direct the clinical practice for thromboprophylaxis in lung cancer treatment.
        The purpose of the current article is to explore the VTE risks associated
        with ambulatory lung cancer treatment and to review the recommended guidelines
        for thromboprophylaxis to guide clinical decision making for patients with
        lung cancer.</Abstract>\r\n    <AuthorList>Cavaliere,Loretta,</AuthorList>\r\n
        \   <AuthorCount>1</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Journal
        Article</DocumentTypeList>\r\n    <DocumentCategory>Journal Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\"
        />\r\n    <TimesNotSelfCited xsi:nil=\"true\" />\r\n    <PMID>23372099</PMID>\r\n
        \   <PublicationSourceTitle>Clinical journal of oncology nursing</PublicationSourceTitle>\r\n
        \   <Volume>17</Volume>\r\n    <Issue>1</Issue>\r\n    <Pagination>74-79</Pagination>\r\n
        \   <PublicationDate>2013-02-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2013</PublicationYear>\r\n
        \   <PublicationSubjectCategoryList />\r\n    <ISSN>1092-1095</ISSN>\r\n    <DOI>10.1188/13.CJON.74-79</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>13</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <PublicationImpactFactorList>0.729,2011,ClosestToPublicationYear|0.729,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>171/190;ONCOLOGY;2011;SC;ClosestToPublicationYear|68/97;NURSING;2011;SC;ClosestToPublicationYear|65/95;NURSING;2011;SS;ClosestToPublicationYear|171/190;ONCOLOGY;2011;SC;MostRecentYear|68/97;NURSING;2011;SC;MostRecentYear|65/95;NURSING;2011;SS;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED STATES</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>62269674</PublicationItemID>\r\n
        \   <Title>Numerical simulations for tumor and cellular immune system interactions
        in lung cancer treatment</Title>\r\n    <Abstract>We investigate a new mathematical
        model that describes lung cancer regression in patients treated by chemotherapy
        and radiotherapy. The model is composed of nonlinear integro-differential
        equations derived from the so-called kinetic theory for active particles and
        a new sink function is investigated according to clinical data from carcinoma
        planoepitheliale. The model equations are solved numerically and the data
        are utilized in order to find their unknown parameters. The results of the
        numerical experiments show a good correlation between the predicted and clinical
        data and illustrate that the mathematical model has potential to describe
        lung cancer regression. Published by Elsevier B. V.</Abstract>\r\n    <AuthorList>Kolev,M,|Nawrocki,S,|Zubik-Kowal,B,</AuthorList>\r\n
        \   <AuthorCount>3</AuthorCount>\r\n    <KeywordList>PROGRESSION|kinetic theory|numerical
        simulations|active particles|Carcinoma planoepitheliale</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>10</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000313705300013</WoSItemID>\r\n
        \   <PublicationSourceTitle>COMMUNICATIONS IN NONLINEAR SCIENCE AND NUMERICAL
        SIMULATION</PublicationSourceTitle>\r\n    <Volume>18</Volume>\r\n    <Issue>6</Issue>\r\n
        \   <Pagination>1473-1480</Pagination>\r\n    <PublicationDate>2013-06-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2013</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Mathematics, Applied|Mathematics, Interdisciplinary
        Applications|Mechanics|Physics, Fluids &amp; Plasmas|Physics, Mathematical</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1007-5704</ISSN>\r\n    <DOI>10.1016/j.cnsns.2012.10.011</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>14</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>ELSEVIER
        SCIENCE BV</CopyrightPublisher>\r\n    <CopyrightCity>AMSTERDAM</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>2.806,2011,ClosestToPublicationYear|2.806,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>5/245;MATHEMATICS, APPLIED;2011;SC;ClosestToPublicationYear|3/92;MATHEMATICS,
        INTERDISCIPLINARY APPLICATIONS;2011;SC;ClosestToPublicationYear|6/132;MECHANICS;2011;SC;ClosestToPublicationYear|5/31;PHYSICS,
        FLUIDS &amp; PLASMAS;2011;SC;ClosestToPublicationYear|4/55;PHYSICS, MATHEMATICAL;2011;SC;ClosestToPublicationYear|5/245;MATHEMATICS,
        APPLIED;2011;SC;MostRecentYear|3/92;MATHEMATICS, INTERDISCIPLINARY APPLICATIONS;2011;SC;MostRecentYear|6/132;MECHANICS;2011;SC;MostRecentYear|5/31;PHYSICS,
        FLUIDS &amp; PLASMAS;2011;SC;MostRecentYear|4/55;PHYSICS, MATHEMATICAL;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>NETHERLANDS</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>62174502</PublicationItemID>\r\n
        \   <Title>LUNG CANCER TREATMENT: A PARADIGM SHIFT TO TARGETED THERAPIES IN
        CLINICAL TRIAL SETTINGS IN ASIA</Title>\r\n    <Abstract />\r\n    <AuthorList>Gupta,J,|Gupta,P,|Kaur,H,|Jindal,R,</AuthorList>\r\n
        \   <AuthorCount>4</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Meeting
        Abstract</DocumentTypeList>\r\n    <DocumentCategory>Conference Proceeding
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000312411101782</WoSItemID>\r\n
        \   <PublicationSourceTitle>VALUE IN HEALTH</PublicationSourceTitle>\r\n    <Volume>15</Volume>\r\n
        \   <Issue>7</Issue>\r\n    <Pagination>A623-A623</Pagination>\r\n    <PublicationDate>2012-11-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2012</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Economics|Health Care Sciences &amp; Services|Health
        Policy &amp; Services</PublicationSubjectCategoryList>\r\n    <ISSN>1098-3015</ISSN>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>15</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>ELSEVIER
        SCIENCE INC</CopyrightPublisher>\r\n    <CopyrightCity>NEW YORK</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>2.191,2011,ClosestToPublicationYear|2.191,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>25/75;HEALTH CARE SCIENCES &amp; SERVICES;2011;SC;ClosestToPublicationYear|12/61;HEALTH
        POLICY &amp; SERVICES;2011;SS;ClosestToPublicationYear|32/320;ECONOMICS;2011;SS;ClosestToPublicationYear|25/75;HEALTH
        CARE SCIENCES &amp; SERVICES;2011;SC;MostRecentYear|12/61;HEALTH POLICY &amp;
        SERVICES;2011;SS;MostRecentYear|32/320;ECONOMICS;2011;SS;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>62142265</PublicationItemID>\r\n    <Title>Patient-tailored
        modulation of the immune system may revolutionize future lung cancer treatment</Title>\r\n
        \   <Abstract>Cancer research has devoted most of its energy over the past
        decades on unraveling the control mechanisms within tumor cells that govern
        its behavior. From this we know that the onset of cancer is the result of
        cumulative genetic mutations and epigenetic alterations in tumor cells leading
        to an unregulated cell cycle, unlimited replicative potential and the possibility
        for tissue invasion and metastasis. Until recently it was often thought that
        tumors are more or less undetected or tolerated by the patient's immune system
        causing the neoplastic cells to divide and spread without resistance. However,
        it is without any doubt that the tumor environment contains a wide variety
        of recruited host immune cells. These tumor infiltrating immune cells influence
        anti-tumor responses in opposing ways and emerges as a critical regulator
        of tumor growth. Here we provide a summary of the relevant immunological cell
        types and their complex and dynamic roles within an established tumor microenvironment.
        For this, we focus on both the systemic compartment as well as the local presence
        within the tumor microenvironment of late-stage non-small cell lung cancer
        (NSCLC), admitting that this multifaceted cellular composition will be different
        from earlier stages of the disease, between NSCLC patients. Understanding
        the paradoxical role that the immune system plays in cancer and increasing
        options for their modulation may alter the odds in favor of a more effective
        anti-tumor immune response. We predict that the future standard of care of
        lung cancer will involve patient-tailor-made combination therapies that associate
        (traditional) chemotherapeutic drugs and biologicals with immune modulating
        agents and in this way complement the therapeutic armamentarium for this disease.</Abstract>\r\n
        \   <AuthorList>Heuvers,Marlies,E|Aerts,Joachim,G|Cornelissen,Robin,|Groen,Harry,|Hoogsteden,Henk,C|Hegmans,Joost,P</AuthorList>\r\n
        \   <AuthorCount>6</AuthorCount>\r\n    <KeywordList>REGULATORY T-CELLS|ANTITUMOR
        IMMUNITY|MAST-CELLS|DENDRITIC CELLS|FOXP3 EXPRESSION|ENDOTHELIAL GROWTH-FACTOR|TUMOR-ASSOCIATED
        MACROPHAGES|NATURAL-KILLER-CELLS|SUPPRESSOR-CELLS|MALIGNANT PLEURAL EFFUSION|lung
        cancer|personalized medicine|immune system|tumor microenvironment|cancer immunology</KeywordList>\r\n
        \   <DocumentTypeList>Review</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>180</NumberOfReferences>\r\n
        \   <TimesCited>2</TimesCited>\r\n    <TimesNotSelfCited>1</TimesNotSelfCited>\r\n
        \   <PMID>23217146</PMID>\r\n    <WoSItemID>000312907500001</WoSItemID>\r\n
        \   <PublicationSourceTitle>BMC CANCER</PublicationSourceTitle>\r\n    <Volume>12</Volume>\r\n
        \   <Pagination />\r\n    <PublicationDate>2012-12-05T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2012</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1471-2407</ISSN>\r\n    <DOI>10.1186/1471-2407-12-580</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>16</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>BIOMED
        CENTRAL LTD</CopyrightPublisher>\r\n    <CopyrightCity>LONDON</CopyrightCity>\r\n
        \   <ArticleNumber>580</ArticleNumber>\r\n    <PublicationImpactFactorList>3.011,2011,ClosestToPublicationYear|3.011,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>77/190;ONCOLOGY;2011;SC;ClosestToPublicationYear|77/190;ONCOLOGY;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,2|2,1,1|3,0,2|4,0,2|5,0,2|6,1,1</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED KINGDOM</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>62075343</PublicationItemID>\r\n
        \   <Title>The Role of Pretreatment PET/CT Parameters in Predicting Response
        After Lung Cancer Treatment</Title>\r\n    <Abstract />\r\n    <AuthorList>Lavaf,A,|Tejwani,A,|DAYA,P,|Atia,M,|Ashamalla,H,</AuthorList>\r\n
        \   <AuthorCount>5</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Meeting
        Abstract</DocumentTypeList>\r\n    <DocumentCategory>Conference Proceeding
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000310542902022</WoSItemID>\r\n
        \   <PublicationSourceTitle>INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY
        PHYSICS</PublicationSourceTitle>\r\n    <Volume>84</Volume>\r\n    <Issue>3</Issue>\r\n
        \   <Pagination>S602-S603</Pagination>\r\n    <PublicationDate>2012-11-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2012</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Oncology|Radiology, Nuclear Medicine &amp;
        Medical Imaging</PublicationSubjectCategoryList>\r\n    <ISSN>0360-3016</ISSN>\r\n
        \   <ConferenceTitle>54th Annual Meeting of the American-Society-for-Radiation-Oncology
        (ASTRO)</ConferenceTitle>\r\n    <ConferenceStartDate>2012-10-28T00:00:00</ConferenceStartDate>\r\n
        \   <ConferenceEndDate>2012-10-31T00:00:00</ConferenceEndDate>\r\n    <ConferenceCity>BOSTON</ConferenceCity>\r\n
        \   <ConferenceStateCountry>MA</ConferenceStateCountry>\r\n    <Rank xsi:nil=\"true\"
        />\r\n    <OrdinalRank>17</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\"
        />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>ELSEVIER SCIENCE INC</CopyrightPublisher>\r\n    <CopyrightCity>NEW
        YORK</CopyrightCity>\r\n    <PublicationImpactFactorList>4.105,2011,ClosestToPublicationYear|4.105,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>45/190;ONCOLOGY;2011;SC;ClosestToPublicationYear|12/116;RADIOLOGY,
        NUCLEAR MEDICINE &amp; MEDICAL IMAGING;2011;SC;ClosestToPublicationYear|45/190;ONCOLOGY;2011;SC;MostRecentYear|12/116;RADIOLOGY,
        NUCLEAR MEDICINE &amp; MEDICAL IMAGING;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>61969788</PublicationItemID>\r\n    <Title>Oxidative
        Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment</Title>\r\n
        \   <Abstract>Nuclear factor erythroid-2 related factor 2 (Nrf2) is a transcription
        factor that regulates protection against a wide variety of toxic insults to
        cells, including cytotoxic cancer chemotherapeutic drugs. Many lung cancer
        cells harbor a mutation in either Nrf2 or its inhibitor Keap1 resulting in
        permanent activation of Nrf2 and chemoresistance. In this study, we sought
        to examine whether this attribute could be exploited in cancer suicide gene
        therapy by using a lentiviral (LV) vector expressing herpes simplex virus
        thymidine kinase (HSV-TK/GCV) under the regulation of antioxidant response
        element (ARE), a cis-acting enhancer sequence that binds Nrf2. In human lung
        adenocarcinoma cells in which Nrf2 is constitutively overexpressed, ARE activity
        was found to be high under basal conditions. In this setting, ARE-HSV-TK was
        more effective than a vector in which HSV-TK expression was driven by a constitutively
        active promoter. In a mouse xenograft model of lung cancer, suicide gene therapy
        with LV-ARE-TK/GCV was effective compared with LV-PGK-TK/GCV in reducing tumor
        size. We conclude that ARE-regulated HSV-TK/GCV therapy offers a promising
        approach for suicide cancer gene therapy in cells with high constitutive ARE
        activity, permitting a greater degree of therapeutic targeting to those cells.
        Cancer Res; 72(23); 6227-35. (C) 2012 AACR.</Abstract>\r\n    <AuthorList>Leinonen,Hanna,M|Ruotsalainen,Anna-Kaisa,|Maatta,Ann-Marie,|Laitinen,Heidi,M|Kuosmanen,Suvi,M|Kansanen,Emilia,|Pikkarainen,Jere,T|Lappalainen,Jari,P|Samaranayake,Haritha,|Lesch,Hanna,P|Kaikkonen,Minna,U|Yla-Herttuala,Seppo,|Levonen,Anna-Liisa,</AuthorList>\r\n
        \   <AuthorCount>13</AuthorCount>\r\n    <KeywordList>NRF2|RESISTANCE|PATHWAY|ANTIOXIDANT
        RESPONSE|CELL-PROLIFERATION|OVARIAN-CANCER|ACTIVATION|EXPRESSION|GROWTH|KEAP1
        MUTATIONS</KeywordList>\r\n    <DocumentTypeList>Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>49</NumberOfReferences>\r\n
        \   <TimesCited>2</TimesCited>\r\n    <TimesNotSelfCited>2</TimesNotSelfCited>\r\n
        \   <PMID>23041549</PMID>\r\n    <WoSItemID>000311893100017</WoSItemID>\r\n
        \   <PublicationSourceTitle>CANCER RESEARCH</PublicationSourceTitle>\r\n    <Volume>72</Volume>\r\n
        \   <Issue>23</Issue>\r\n    <Pagination>6227-6235</Pagination>\r\n    <PublicationDate>2012-12-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2012</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0008-5472</ISSN>\r\n    <DOI>10.1158/0008-5472.CAN-12-1166</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>18</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>AMER ASSOC
        CANCER RESEARCH</CopyrightPublisher>\r\n    <CopyrightCity>PHILADELPHIA</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>7.856,2011,ClosestToPublicationYear|7.856,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>12/190;ONCOLOGY;2011;SC;ClosestToPublicationYear|12/190;ONCOLOGY;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,2|2,0,2|3,0,2|4,0,2|5,0,2|6,0,2|7,0,2|8,0,2|9,0,2|10,0,2|11,0,2|12,0,2|13,0,2</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>PA</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>61758131</PublicationItemID>\r\n    <Title>Completion
        pneumonectomy for lung cancer treatment: early and long term outcomes</Title>\r\n
        \   <Abstract>Background: To analyze the experience of completion pneumonectomy
        for lung cancer at a single institution in China.  Methods: From January 1988
        to December 2007, 92 patients underwent completion pneumonectomy for the treatment
        of lung cancer. The indications were second primary lung cancer (n = 51),
        Local metastasis (n = 37) and Lung metastasis (n = 4). The median interval
        between the primary operation and CP was 24.4 months (1.5-145 m).  Results:
        There was no intraoperative deaths. The CP procedure lasted 4.3 h (1.5-8 h).
        Blood loss in the CP performance was 1854.5 ml (200-9100 ml) 9 (9.78%) patients
        died in the postoperative period: pulmonary embolism (n = 2), disseminated
        intravascular coagulation (DIC) after the multisystem failure (n = 1), respiratory
        failure after contralateral pneumonia (n = 5), bronchopleural fistula (BPF)
        with acute respiratory distress syndrome (ARDS) (n = 1) 31(33.7%) patients
        had at least one major nonfatal complication. The 1, 3 and 5 year survival
        rates were 81%, 26% and 14% respectively.  Conclusions: Completion pneumonectomy
        for lung cancer is a safe surgical procedure for the skilled surgeon though
        it has a relatively higher complications and the long-term survival is acceptable.</Abstract>\r\n
        \   <AuthorList>Zhang,Peng,|Jiang,Chao,|He,Wenxin,|Song,Nan,|Zhou,Xiao,|Jiang,Gening,</AuthorList>\r\n
        \   <AuthorCount>6</AuthorCount>\r\n    <KeywordList>COMPLICATIONS|MORBIDITY|MORTALITY|2ND|EXPERIENCE|lung
        cancer|follow-up|completion pneumonectomy</KeywordList>\r\n    <DocumentTypeList>Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>20</NumberOfReferences>\r\n
        \   <TimesCited>1</TimesCited>\r\n    <TimesNotSelfCited>1</TimesNotSelfCited>\r\n
        \   <PMID>23046489</PMID>\r\n    <WoSItemID>000311290800001</WoSItemID>\r\n
        \   <PublicationSourceTitle>JOURNAL OF CARDIOTHORACIC SURGERY</PublicationSourceTitle>\r\n
        \   <Volume>7</Volume>\r\n    <Pagination />\r\n    <PublicationDate>2012-10-09T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2012</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Cardiac &amp; Cardiovascular Systems</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1749-8090</ISSN>\r\n    <DOI>10.1186/1749-8090-7-107</DOI>\r\n    <ConferenceStartDate
        xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank
        xsi:nil=\"true\" />\r\n    <OrdinalRank>19</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>BIOMED CENTRAL LTD</CopyrightPublisher>\r\n    <CopyrightCity>LONDON</CopyrightCity>\r\n
        \   <ArticleNumber>107</ArticleNumber>\r\n    <PublicationImpactFactorList>1.187,2011,ClosestToPublicationYear|1.187,2011,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>87/117;CARDIAC &amp; CARDIOVASCULAR SYSTEMS;2011;SC;ClosestToPublicationYear|87/117;CARDIAC
        &amp; CARDIOVASCULAR SYSTEMS;2011;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,1|2,0,1|3,0,1|4,0,1|5,0,1|6,0,1</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED KINGDOM</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n</ArrayOfPublicationItem>"
    http_version: 
  recorded_at: Sun, 08 Sep 2013 20:09:52 GMT
recorded_with: VCR 2.5.0
